TIGIT and hepatocellular carcinoma: Notably, these HCC-enriched ICOS+ TRM frequently also expressed one or more co-inhibitory immune checkpoint receptors including PD-1, TIGIT and Tim-3 (Figures 2C, D and Supplementary Figures 1C, D).